BRIEF—Jasper Therapeutics asks for $90 million in public offering

Jasper Therapeutics is seeking to raise $90 million in a public offering of common stock, which is expected to close on or around January 27, 2023.

The company is focused on developing novel antibody therapies targeting c-Kit, to address diseases such as chronic spontaneous urticaria and myelodysplastic syndromes (MDS).

Lead candidate briquilimab is a monoclonal antibody, also under development as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease, Fanconi anemia and severe combined immunodeficiency.

Jasper plans to use the money for general corporate purposes including capital expenditures, working capital and other expenses.